| Imran Plumb, MD | |
|
1400 Bryan Dr, Suite 208, Durant, OK 74701-2156 | |
| (580) 931-2256 | |
| Not Available |
| Full Name | Imran Plumb |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 14 Years |
| Location | 1400 Bryan Dr, Durant, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275827305 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 30916 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mays Housecall Home Health Of Durant | Durant, OK | Home health agency |
| Carter Healthcare Of South Oklahoma, Llc | Ardmore, OK | Home health agency |
| Millennium Home Care Of Se Oklahoma | Hugo, OK | Home health agency |
| Tendercare Home Health Of Kingston, Llc | Kingston, OK | Home health agency |
| Mays Housecall Home Health Of Antlers, Llc | Antlers, OK | Home health agency |
| Guardian Hospice Of Oklahoma | Calera, OK | Hospice |
| Integris Marshall County Medical Center | Madill, OK | Hospital |
| Alliancehealth Durant | Durant, OK | Hospital |
| Atoka County Medical Center | Atoka, OK | Hospital |
| Texoma Medical Center | Denison, TX | Hospital |
| Calera Manor, Llc | Calera, OK | Nursing home |
| Oakridge Nursing Center | Durant, OK | Nursing home |
| Southern Pointe Living Center | Colbert, OK | Nursing home |
| Four Seasons Rehabilitation & Care | Durant, OK | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Marshall County Hma, Llc | 5193985653 | 10 |
News Archive
Around five million people in the UK are currently being treated for asthma. Of these, a quarter of a million are unable to get good control of their condition, resulting in frequent, severe, or even life-threatening attacks. A new study brings hope to these patients by investigating whether the drug Omalizumab can be better targeted.
Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.
Researchers have caught a protein they previously implicated in a variety of cancer-promoting roles performing a vital function in cell division, survival and development of brain tumors.
Experimental evidence confirms what surveys have long suggested: Physicians are more likely to prescribe antibiotics when they believe there is a high expectation of it from their patients, even if they think the probability of bacterial infection is low and antibiotics would not be effective, according to a study published by the American Psychological Association.
Antibodies are among the most commonly used reagents in life-science laboratories employed in everyday experiments, diagnostics and clinical tests. The specificity displayed by antibodies makes them versatile lab tools; however, sourcing the most appropriate antibody can be costly and time consuming
› Verified 8 days ago
| Entity Name | Durant Hma Physician Management Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043361116 PECOS PAC ID: 3375638976 Enrollment ID: O20070927000304 |
News Archive
Around five million people in the UK are currently being treated for asthma. Of these, a quarter of a million are unable to get good control of their condition, resulting in frequent, severe, or even life-threatening attacks. A new study brings hope to these patients by investigating whether the drug Omalizumab can be better targeted.
Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.
Researchers have caught a protein they previously implicated in a variety of cancer-promoting roles performing a vital function in cell division, survival and development of brain tumors.
Experimental evidence confirms what surveys have long suggested: Physicians are more likely to prescribe antibiotics when they believe there is a high expectation of it from their patients, even if they think the probability of bacterial infection is low and antibiotics would not be effective, according to a study published by the American Psychological Association.
Antibodies are among the most commonly used reagents in life-science laboratories employed in everyday experiments, diagnostics and clinical tests. The specificity displayed by antibodies makes them versatile lab tools; however, sourcing the most appropriate antibody can be costly and time consuming
› Verified 8 days ago
| Entity Name | Lakeside Family Medicine |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295064178 PECOS PAC ID: 6204971112 Enrollment ID: O20100303000625 |
News Archive
Around five million people in the UK are currently being treated for asthma. Of these, a quarter of a million are unable to get good control of their condition, resulting in frequent, severe, or even life-threatening attacks. A new study brings hope to these patients by investigating whether the drug Omalizumab can be better targeted.
Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.
Researchers have caught a protein they previously implicated in a variety of cancer-promoting roles performing a vital function in cell division, survival and development of brain tumors.
Experimental evidence confirms what surveys have long suggested: Physicians are more likely to prescribe antibiotics when they believe there is a high expectation of it from their patients, even if they think the probability of bacterial infection is low and antibiotics would not be effective, according to a study published by the American Psychological Association.
Antibodies are among the most commonly used reagents in life-science laboratories employed in everyday experiments, diagnostics and clinical tests. The specificity displayed by antibodies makes them versatile lab tools; however, sourcing the most appropriate antibody can be costly and time consuming
› Verified 8 days ago
| Entity Name | Marshall County Hma, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356874374 PECOS PAC ID: 5193985653 Enrollment ID: O20120409000632 |
News Archive
Around five million people in the UK are currently being treated for asthma. Of these, a quarter of a million are unable to get good control of their condition, resulting in frequent, severe, or even life-threatening attacks. A new study brings hope to these patients by investigating whether the drug Omalizumab can be better targeted.
Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.
Researchers have caught a protein they previously implicated in a variety of cancer-promoting roles performing a vital function in cell division, survival and development of brain tumors.
Experimental evidence confirms what surveys have long suggested: Physicians are more likely to prescribe antibiotics when they believe there is a high expectation of it from their patients, even if they think the probability of bacterial infection is low and antibiotics would not be effective, according to a study published by the American Psychological Association.
Antibodies are among the most commonly used reagents in life-science laboratories employed in everyday experiments, diagnostics and clinical tests. The specificity displayed by antibodies makes them versatile lab tools; however, sourcing the most appropriate antibody can be costly and time consuming
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Imran Plumb, MD 1400 Bryan Dr, Suite 208, Durant, OK 74701-2156 Ph: (580) 931-2256 | Imran Plumb, MD 1400 Bryan Dr, Suite 208, Durant, OK 74701-2156 Ph: (580) 931-2256 |
News Archive
Around five million people in the UK are currently being treated for asthma. Of these, a quarter of a million are unable to get good control of their condition, resulting in frequent, severe, or even life-threatening attacks. A new study brings hope to these patients by investigating whether the drug Omalizumab can be better targeted.
Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.
Researchers have caught a protein they previously implicated in a variety of cancer-promoting roles performing a vital function in cell division, survival and development of brain tumors.
Experimental evidence confirms what surveys have long suggested: Physicians are more likely to prescribe antibiotics when they believe there is a high expectation of it from their patients, even if they think the probability of bacterial infection is low and antibiotics would not be effective, according to a study published by the American Psychological Association.
Antibodies are among the most commonly used reagents in life-science laboratories employed in everyday experiments, diagnostics and clinical tests. The specificity displayed by antibodies makes them versatile lab tools; however, sourcing the most appropriate antibody can be costly and time consuming
› Verified 8 days ago
Saurabh Patel, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1801 Chukka Hina, Durant, OK 74701 Phone: 580-920-2100 | |
Nirmal Jot Kaur, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1400 Bryan Dr Ste 206, Durant, OK 74701 Phone: 580-931-2047 | |
Dr. Vivek Khetpal, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2701 W. University Blvd, Durant, OK 74701 Phone: 580-931-0500 Fax: 580-920-8027 | |
Satish Ramesh Bagdure, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1400 Bryan Dr Ste 208, Durant, OK 74701 Phone: 580-931-2256 | |
Deepak S. Jaiswal, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 702 Bryan Dr, Suite 100, Durant, OK 74701 Phone: 580-924-4704 Fax: 580-924-6001 | |
Dr. Kevin J Gordon, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1610 W University Blvd, Durant, OK 74701 Phone: 580-924-3400 Fax: 580-924-7732 |